Acute myeloid leukemia cells exposed to cytarabine and idarubicin (AML cells (Ara-C/Ida))

Acute myeloid leukemia (AML) cells exposed to cytarabine and idarubicin represent a specific clinical and experimental state of hematologic malignancy undergoing induction therapy. AML is characterized by the clonal expansion of immature myeloid precursors (blasts) that fail to differentiate, leading to bone marrow failure (StatPearls, 2023). The combination of cytarabine, a nucleoside analog, and idarubicin, an anthracycline, is a standard "7+3" induction regimen designed to eradicate these leukemic cells (NCI, 2023). Cytarabine interferes with DNA synthesis by acting as a pyrimidine analog that is incorporated into DNA, while idarubicin causes DNA damage through intercalation and topoisomerase II inhibition (PubChem, 2024). Studying these cells provides insights into the mechanisms of chemotherapy-induced cell death and the development of drug resistance, which remains a significant challenge in AML treatment (PubMed, 2022). This cellular state is often used in research to evaluate the efficacy of novel agents in sensitizing resistant blasts to standard chemotherapy. The interaction between these drugs and the AML cells results in the activation of apoptotic pathways and cell cycle arrest (NIH, 2023). Monitoring the response of these cells is critical for determining the success of induction therapy and the need for subsequent consolidation or stem cell transplantation.

Other names

AML blasts7+3 treated AML cellsAcute myeloid leukemia cells

Cytarabine acts as a pyrimidine analog that inhibits DNA polymerase and DNA synthesis after being phosphorylated into its active form, cytarabine triphosphate (PubChem, 2024). Idarubicin is an anthracycline that intercalates between DNA base pairs and inhibits the enzyme topoisomerase II, preventing DNA religation and inducing double-strand breaks (NIH, 2023). Together, these agents synergistically induce apoptosis in malignant myeloid cells by disrupting genomic integrity and inhibiting cellular replication.